The role of neoadjuvant chemotherapy for breast cancer treatment

Breast Cancer

Volumn 9, Issue 1, 2002, Pages 8-14

  Ikeda, Tadashi ^a   Jinno, Hiromitsu ^a   Matsui, Akira ^b   Masamura, Shigeru ^c   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY   (Japan)

^b KEIO UNIVERSITY HOSPITAL   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Preoperative chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MORTALITY; PROGNOSIS; REVIEW; SURVIVAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOADJUVANT THERAPY; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0036051734     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967540     Document Type: Review

References (40)

1. Goldie JH, Coldman AJ: A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979. (Pubitemid 10138923)
2. Fisher B, Gunduz N, Saffer EA: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43:1488-1492, 1983. (Pubitemid 13122535)
3. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998. (Pubitemid 28363030)
4. Mauriac L, MacGrogan G, Avril A, et al: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institute Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10:47-52, 1999. (Pubitemid 29090591)
5. Markis A, Powles TJ, Ashley SE, et al: A reduction in the requirement for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9:1179-1184, 1998. (Pubitemid 28552806)
6. Scholl SM, Fourquet A, Asselain B, et al: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6, Eur J Cancer 30A:645-652, 1994. (Pubitemid 24164252)
7. Jakesz R: Comparison of pre-vs. postoperative chemotherapy in breast cancer patients: Four-year results of Austrian Breast & Colorectal Study Group (ABCSG) Trial 7. #125, Proc Am Soc Clin Oncol, 2001.
8. Gradishar WJ: Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer, Oncology 11(Supp 8):15-18, 1997. (Pubitemid 27357871)
9. Morrell LE, Lee YJ, Hurtey J, et al: A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma. Cancer 82:503-511, 1998. (Pubitemid 28112989)
10. Bonadonna G, Balagussa P, Brambilla C, et al: Primary chemotherapy in operable breast cancer: eightyear experience at the Milan Cancer Institute. J Clin Concol 16:93-100, 1998. (Pubitemid 28041584)
11. Cocconi G, Bisagni G, Ceci G, et al: Tree new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial. Breast Cancer Res Treat 56:125-132, 1999. (Pubitemid 29494830)
12. Buzdar AU, Singletary SE, Theriault RL, et al: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicine, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17:3412-3417, 1999. (Pubitemid 29517908)
13. Ezzat AA, Ibrahim EM, Ajarim DS, et al: High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin. Breast Cancer Res Treat 62:237-244, 2000.
14. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999. (Pubitemid 29075229)
15. Minckwitz G, Costa SD, Eiermann W, et al: Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 17:1999-2005, 1999. (Pubitemid 29318827)
16. Miller KD, McCaskill-Stevens W, Loesch SJ, et al: Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 17:3033-3037, 1999. (Pubitemid 29470630)
17. E Luporsi, L Vanlemmens, B Coudert, et al: 6 cycles of FEC 100 vs 6 cycles of epirubicin-docetaxel (ED) as neoadjuvant chemotherapy in operable breast cancer patients (PTS): Preliminary results of a randomized phase II trial of GIREC S01. #355, Proc Am Soc Clin Oncol, 2000.
18. Raab GH, Minckwitz G v, Blohmer J U: Results of the GEPARDO trial (German Preoperative adriamycin docetaxel); A phase IIB study comparing the combination of dose-intensified adriamycin with or without tamoxifen in patients with operable breast cancer. #322, Proc Am Soc Clin Oncol, 2000.
19. Tubiana-Hulin M, Dieras V, Fumoleau P, et al: Phase II trial combining docetaxel (D) doxorubicine (DOX) as neo adjuvant treatment in patients (PTS) with operable breast carcinoma (BC). #495, Proc Am Soc Clin Oncol, 2000.
20. Lara F, De la Garza J, Ramirez T: High pathological complete response (pCR) after neoadjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer. #492, Proc Am Soc Clin Oncol, 2000.
21. Limentani SA, Erban JK, Sprague KA: Phase II study of doxorubicine and docetaxel as neoadjuvant therapy for women with stage KB or EI breast cancer. #511, Proc Am Soc Clin Oncol, 2000.
22. Ikeda T, Masamura S, Matsui A, et al: Neoadjuvant chemotherapy with alternating sequential docetaxel (DOC) and doxorubicine/cyclophosphamide (AC) in locally advanced breast cancer (LABC): A Pilot study. Eur J Cancer 36(Suppl 5):S78, 2000.
23. Burstein HJ, Harris LN, Kaelin CM, et al: Preoperative herceptin and paclitaxel (Taxol) for HER2 overexpressing (HER2+) stage II/W breast cancer.#100, Proc Am Soc Clin Oncol, 2001.
24. Davidson NE, Kennedy JK, and Armstrong DK: Dose-intensive chemotherapy. In Diseases of the breast, second ed. Eds Harris JR, Lippman ME, Morrow M, Osborne CK, Lippinncott Williams & Wilkins, Philadelphia, 2000, pp633-644.
25. Green MC, Buzdar AU, Smith T, et al: Weekly paclitaxel (P) followed by FAC in the neo-adjuvant setting provides improved pathologic complete remission (PCR) rates compared to standard paclitaxel followed by FAC therapy-Preliminary results of an ongoing prospective randomized trial. 29, Proc Am Soc Clin Oncol, 2001.
26. Tubiana-Hulin M, Romieu G, Fumoleau P, et al: A randomized, parallel study of 4 or6 cycles of Adriamycin/Taxol (paclitaxel) (AT) as neoadjuvant treatment of breast cancer, #1879, Proc Am Soc Clin Oncol, 2001.
27. Hutcheon AW, Ogston KN, Heys SD, et al: Primary chemotherapy in the treatment of breast cancer: Significcantly enhanced clinical and pathological response with docetaxel. #317, Proc Am Soc Clin Oncol, 2000.
28. Stebbing J, Gaya A: The evidence-based use of induction chemotherapy in breast cancer, Breast Cancer 8:23-37, 2001.
29. Paik S, Bryant J, Park C, et al: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer, J Natl Cancer Inst 90:1361-1370, 1998. (Pubitemid 28439960)
30. Markis A, Powles TJ, Dowsett M, et al: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3:593-600, 1997. (Pubitemid 27211838)
31. Billgren AM, Rutqvist LE, Tani E, et al: Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival. Acta Oncol 38:597-601, 1999. (Pubitemid 29333740)
32. Fujii H, Nakamura K, Kubo A, et al: 99mTc-MIBI scintigraphy as an indicator of the chemosensitivity of anthracyclines in patients with breast cancer. Anticancer Res 18 (6 B):4601-4605, 1998. (Pubitemid 29042029)
33. Mankoff DA, Dunnwald LK, Gralow JR, et al: Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. Cancer 1;85:2410-2423, 1999. (Pubitemid 29244850)
34. Ciamiello A, Del Vecchio S, Silvestro P, et al: Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuant chemotherapy for locally advanced breast cancer. J Clin Oncol 16:1677-1683, 1988.
35. Wolff AC, and Davidson NE: Primary systemic therapy in operable breast cancer, J Clin Oncol 18:1558-1569, 2000. (Pubitemid 30205403)
36. Miller KD, McCaskill SW, Sisk J, et al: Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer. A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 17:3033-3037, 1999. (Pubitemid 29470630)
37. Abraham DC, Jones RC, Jones SE, et al: Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 78:91-100, 1996. (Pubitemid 26189909)
38. Hiramatsu H, Enomoto K, Ikeda T, et al: The role of contrast-enhanced high resolution MRI in the surgical planning of breast cancer. Breast Cancer 4 (4):285-290, 1997.
39. Nason KS, Anderson BO, Byrd DR, et al: Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 89:2187-2194, 2000.
40. Breslin TM, Cohen L, Sahin A, et al: Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 18:3480-3486, 2000.